ARGATROBAN 1 MG
ARGATROBAN : 1 MG · DIN 02548968 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is ARGATROBAN?
ARGATROBAN 1 MG contains ARGATROBAN : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02548968, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Jan-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ARGATROBAN used for?
Anticoagulant therapy in patients with heparin-induced thrombocytopenia syndrome.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02548968 |
|---|---|
| Brand name | ARGATROBAN |
| Generic / active ingredient | ARGATROBAN : 1 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 1 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AE03 ARGATROBAN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jan-2025 |
How is it administered?
Initial dose 2 mcg/kg/min continuous infusion (adults without hepatic impairment). Adjust to steady-state aPTT 1.5-3.0 times baseline (max 10 mcg/kg/min or 100 seconds).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Diluted solutions: 24h at 15-25°C (light) or 48h at 2-8°C (dark). (Note: Specific vial storage not in provided text snippet).
How is it supplied?
Concentrate: 250 mg/2.5 mL single-use vials. Ready to use: 50 mg/50 mL single-use vials.
Contraindications
Active major bleeding; hypersensitivity to the drug or any ingredient; hereditary fructose intolerance.
Warnings and precautions
Hemorrhage risk (monitor hematocrit/BP); use caution in hepatic disease; monitor aPTT; all parenteral anticoagulants must be discontinued before starting.
What can be used instead?
Other Canadian products sharing ATC code B01AE03 ARGATROBAN. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARGATROBAN | 100 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02243835 |
Who else supplies ARGATROBAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ARGATROBAN appears in 4 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.